Cancer cells often exhibit altered metabolism to support their rapid growth and survival. This includes increased glucose uptake and aerobic glycolysis, known as the Warburg effect. Targeting metabolic pathways, such as through IDH inhibitors and glutaminase inhibitors, offers a potential therapeutic strategy.
